High reproducibility of tumor hypoxia evaluated by 18F- fluoromisonidazole pet for head and neck cancer

Journal of Nuclear Medicine

Volumn 54, Issue 2, 2013, Pages 201-207

  Okamoto, Shozo ^a   Shiga, Tohru ^a   Yasuda, Koichi ^a   Ito, Yoichi M ^a   Magota, Keiichi ^a   Kasai, Katsuhiko ^a   Kuge, Yuji ^b   Shirato, Hiroki ^a   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

18F FMISO; Head and neck cancer; Reproducibility; Tumor hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; HEAD AND NECK CANCER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPOXIA; IMAGE ANALYSIS; IMAGE QUALITY; MAXIMUM STANDARDIZED UPTAKE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIOLOGICAL PARAMETERS; RADIOSENSITIVITY; REPRODUCIBILITY; TUMOR HYPOXIA; TUMOR TO BLOOD RATIO; TUMOR TO MUSCLE RATIO;

ADULT; AGED; ANOXIA; FLUORINE RADIOISOTOPES; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MISONIDAZOLE; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION ONCOLOGY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84873549723     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.109330     Document Type: Article

References (28)

1. Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells. 2010;28:639-648.
2. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol. 2005;77:18-24.
3. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441.
4. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79-87.
5. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391-398.
6. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260.
7. 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70:1219-1228.
8. 18F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med. 2009;50:1020-1027.
9. Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008;70:2-13.
10. 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235-242.
11. 18F]-2-fluoro-29-deoxyglucose): an appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol. 2004;180:616-622.
12. Jakoby BW, Bercier Y, Conti M, Casey ME, Bendriem B, Townsend DW. Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol. 2011;56:2375-2389.
13. Panin VY, Kehren F, Michel C, Casey M. Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging. 2006;25:907-921.
14. Pluim JP, Maintz JB, Viergever MA. Mutual-information-based registration of medical images: a survey. IEEE Trans Med Imaging. 2003;22:986-1004.
15. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, IA: The Iowa State University Press; 1980:190-191.
16. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
17. 18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol. 2005;50:2209-2224.
18. 18F]FMISO-PET in HNSCC: when is the contrast best? Nuklearmedizin. 2011;50:22-27.
19. Cherry SR, Woods RP, Hoffman EJ, Mazziotta JC. Improved detection of focal cerebral blood flow changes using three-dimensional positron emission tomography. J Cereb Blood Flow Metab. 1993;13:630-638.
20. 18F-FDG PET oncology studies performed on an LSO-based scanner. J Nucl Med. 2006;47:23-31.
21. Bayer C, Shi K, Astner ST, Maftei CA, Vaupel P. Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys. 2011;80:965-968.
22. 18F]fluoromisonidazole PET imaging. Phys Med Biol. 2012;57:1675-1684.
23. Choi W, Lee SW, Park SH, et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiother Oncol. 2010;97:176-182.
24. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol. 2011;101:369-375.
25. 18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer. Int J Radiat Oncol Biol Phys. 2013;85:142-147.
26. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
27. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
28. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695-704.